I know that guys who haven’t been snipped hate to hear this, but a new study in South Africa might make you want to revisit the subject of circumcision in terms of HIV, HPV, genital warts, etc. (and make women check out prospective partners a little more closely). The study shows that circumcision reduces the risk of contracting HIV by 76 percent.
76 percent. WOW. And of course, if you don’t get HIV, you’re not going to pass it along to your partner(s), either.
While it’s hard to say whether those statistics would hold up in the US, where life, health and risks are different, it’s hard to imagine that circumcision could make less than a very worthwhile difference in transmission rates. And it’s not just a matter of cleanliness. The cells in the foreskin are particularly vulnerable to viruses.
Oh, and then there’s the nasty subject of genital warts. Circumcision cuts (sorry) that chance by 28-34 percent, too, according to another randomized trial in Africa.
HPV? Not so much. One study found a 27.9% prevalence of high-risk HPV genotypes in uncircumcised males and only an 18.0% prevalence in circumcised males. Their female partners’ risk was 38.7% (uncircumcised partner) and 27.8% (circumcised partner) and it is, of course, impossible to know which way the infection went. But that’s still significant, either as an adjunct to the HPV vaccine series—whether Gardasil or Cervarix—or as part of a well-thought out strategy to lower risk.
As reported by Michael Smith for MedPage Today: “The procedure offers limited protection against most high-risk types, (researchers) noted, while the HPV vaccine is highly effective, but only against a limited number of genotypes. "The two interventions are likely to have important synergistic effects," they concluded.
The odd thing is that Medicaid, which serves some of our most vulnerable populations, doesn’t pay for circumcision in 16 states, and yet the US is currently paying for males to get circumcised in Swaziland to the total tune of $30 million. Talk about “things that make you go hmmmmmmm…”
The current pro-Gardasil campaign has perhaps made many people lose sight of the fact that there’s a heck of a lot worse things out there than HPV. With rates of women getting their annual check-ups already dropping in Australia, where Gardasil has been provided free by the national health system, it’s clear that the vaccine carries a subconscious feeling of… phew, I’m safe from STDs.
You’re not. Whether you choose Gardasil or not, just remember that a multi-pronged (sorry again) approach to sexual health is crucial. Keep your immune system healthy (get enough sleep and enough veggies and fruits, quit smoking etc.), use condoms (which will help against HPV and HIV but won't eliminate the risk, particularly for HPV), and apply the infamous Seinfeld “sponge-worthy” criteria to potential partners (is he/she really worth it?).
And guys, it’s up to you. If you’re not circumcised, think about it for your sake and your partner’s sake. Would you do it? If not, why not?
Showing posts with label Cervarix. Show all posts
Showing posts with label Cervarix. Show all posts
Thursday, July 21, 2011
Monday, March 29, 2010
Pre- Gardasil Essential for Sexually Active Women—the HPV Test
Question: would you get a possibly risky vaccine if you thought it was going to be of little, if any, benefit?
Answer: yes, if you follow current medical advice and fail to do your own risk/benefit analysis.
Gardasil, the anti-HPV vaccine that is marketed for the prevention of cervical cancer, is currently approved for use in girls and boys from age 9 to 26 in the US. It’s also approved for women up to age 45 in Australia and may soon be approved for women up to age 45 in the US, too.
However, Gardasil doesn’t cure existing infections. There’s even some evidence that it might cause existing infections to become persistent—Merck’s trial originally showed that women with existing infections were more than 46 percent more likely to suffer a lesion, although they then determined that the study was “unbalanced.” After subtracting women who had extra risk factors, such as a smoking habit, Merck found that the vaccine conferred a very slight benefit. Overall, the combined studies showed an extra risk of a little more than 11 percent from vaccination with Gardasil for infected women. Even in clinical trials that include only uninfected women, so far the results come in at just a 17-45 percent reduction in cervical abnormalities caused by all types of HPV.
Since up to 80 percent of women will be infected with HPV at some point in their life, particularly in the earlier, usually more sexually active years, it’s recommended that the vaccine be administered—at a cost of roughly $500, including the $360 cost of shots and administration—before a child becomes sexually active.
That makes sense as long as you’re OK with the potential side effects. (The FDA says those are limited to fainting and blood clots, although it’s looking into some mighty peculiar cases of rapid-onset ALS “mediated by immune response.” Anecdotal evidence shows a possible risk of post- Gardasil autoimmune disease and neurological issues, including intermittent and ongoing paralysis, seizures, arthritis, Guillaine-BarrĂ©, Graves Disease, etc.; however, the FDA and CDC consider the links to be statistically insignificant.)
But I’m completely at a loss to understand why the CDC advises that getting an HPV test ahead of vaccination is unnecessary.
Sure, that’s almost certainly true for a kid who has yet to have sex. Although HPV has been found in non-abused children, even newborns, because the virus is spread skin-to-skin, the vast majority of cases are spread sexually. (Of course, the obvious issue here is that, if you can find an older teenager willing to say in front of their parents that they’re having sex—wow.)
And there are limits to the effectiveness of the HPV test. Although the current test is sensitive to 14 high-risk strains, it can’t yet tell you which strain you’ve been infected with, though a follow-up test IS available that can check for extra-high risk 16 and 18 if the first test is positive. It can’t tell if you have a “hidden” infection, nor can it tell you if you have had HPV in the past and are now almost certainly immune to that strain.
We also have to get over the idea that we have sweat sleeplessly or go in brandishing swords if an HPV test is positive. It’s positive? So what? Your immune system is just busy working on flushing it out and creating an immunity. What YOU have to do is work on supporting your immune system by eating your fruits and veggies, giving up the ciggies and getting enough zzzzs. You also have to protect any partner(s) with some very safe sex. Then get another test in a year or so.
Right now, the HPV test is recommended only for women older than age 30 in combination with Pap smears. (And it’s worth noting that when you get a combination Pap/HPV test, you can relax with a 99.84 percent certainty that you won’t develop cervical cancer within the next three years if the results are negative. Seems like a no-brainer to me.)
However, if it were me contemplating getting three expensive and not-without-risk shots of Gardasil or Cervarix, I’d sure want to find out, as best I could, whether there was any point at all.
© 2010 www.gardasilhpv.com . Permission is freely given to reproduce the first paragraph of this article, along with a link back to this site and the entirety of the article. For other uses, please contact Kristin at gardasilhpv@gmail.com.
Answer: yes, if you follow current medical advice and fail to do your own risk/benefit analysis.
Gardasil, the anti-HPV vaccine that is marketed for the prevention of cervical cancer, is currently approved for use in girls and boys from age 9 to 26 in the US. It’s also approved for women up to age 45 in Australia and may soon be approved for women up to age 45 in the US, too.
However, Gardasil doesn’t cure existing infections. There’s even some evidence that it might cause existing infections to become persistent—Merck’s trial originally showed that women with existing infections were more than 46 percent more likely to suffer a lesion, although they then determined that the study was “unbalanced.” After subtracting women who had extra risk factors, such as a smoking habit, Merck found that the vaccine conferred a very slight benefit. Overall, the combined studies showed an extra risk of a little more than 11 percent from vaccination with Gardasil for infected women. Even in clinical trials that include only uninfected women, so far the results come in at just a 17-45 percent reduction in cervical abnormalities caused by all types of HPV.
Since up to 80 percent of women will be infected with HPV at some point in their life, particularly in the earlier, usually more sexually active years, it’s recommended that the vaccine be administered—at a cost of roughly $500, including the $360 cost of shots and administration—before a child becomes sexually active.
That makes sense as long as you’re OK with the potential side effects. (The FDA says those are limited to fainting and blood clots, although it’s looking into some mighty peculiar cases of rapid-onset ALS “mediated by immune response.” Anecdotal evidence shows a possible risk of post- Gardasil autoimmune disease and neurological issues, including intermittent and ongoing paralysis, seizures, arthritis, Guillaine-BarrĂ©, Graves Disease, etc.; however, the FDA and CDC consider the links to be statistically insignificant.)
But I’m completely at a loss to understand why the CDC advises that getting an HPV test ahead of vaccination is unnecessary.
Sure, that’s almost certainly true for a kid who has yet to have sex. Although HPV has been found in non-abused children, even newborns, because the virus is spread skin-to-skin, the vast majority of cases are spread sexually. (Of course, the obvious issue here is that, if you can find an older teenager willing to say in front of their parents that they’re having sex—wow.)
And there are limits to the effectiveness of the HPV test. Although the current test is sensitive to 14 high-risk strains, it can’t yet tell you which strain you’ve been infected with, though a follow-up test IS available that can check for extra-high risk 16 and 18 if the first test is positive. It can’t tell if you have a “hidden” infection, nor can it tell you if you have had HPV in the past and are now almost certainly immune to that strain.
We also have to get over the idea that we have sweat sleeplessly or go in brandishing swords if an HPV test is positive. It’s positive? So what? Your immune system is just busy working on flushing it out and creating an immunity. What YOU have to do is work on supporting your immune system by eating your fruits and veggies, giving up the ciggies and getting enough zzzzs. You also have to protect any partner(s) with some very safe sex. Then get another test in a year or so.
Right now, the HPV test is recommended only for women older than age 30 in combination with Pap smears. (And it’s worth noting that when you get a combination Pap/HPV test, you can relax with a 99.84 percent certainty that you won’t develop cervical cancer within the next three years if the results are negative. Seems like a no-brainer to me.)
However, if it were me contemplating getting three expensive and not-without-risk shots of Gardasil or Cervarix, I’d sure want to find out, as best I could, whether there was any point at all.
© 2010 www.gardasilhpv.com . Permission is freely given to reproduce the first paragraph of this article, along with a link back to this site and the entirety of the article. For other uses, please contact Kristin at gardasilhpv@gmail.com.
Labels:
Cervarix,
Gardasil,
HPV test,
older women,
sexually active
Saturday, October 10, 2009
Dr. Diane Harper Badly Misquoted on Gardasil and Cervarix
I’m not a regular reader of the Guardian’s “woo-medicine”-debunking columnist Ben Goldacre, and when I do read him I often disagree with him.
But he hit a home run with his latest Bad Science column.
He took apart a front page Sunday Express article that has already been widely disseminated around scare sites on the Internet. Of course, you can’t read it on the Sunday Express site anymore because it's been removed. Probably because Dr Diane Harper, who was quoted as saying that HPV vaccines are more dangerous than cervical cancer, is about to sue the pin-striped pants off the always-lurid Express. Or so I hope.
I’ve often felt sorry for Dr Harper. She seems like a forthright, intelligent scientist who removes herself from Merck’s marketing hysteria to make sensible cautionary comments about the Gardasil vaccine, which she has worked on and in general supports. But her comments are frequently taken out of context and paraded around the web as if she were an anti-vaccine crusader.
As someone who is wary of Gardasil to the point of thus far turning it down for my daughters, who have a family history of autoimmune disease; as someone who would like to see an awful lot of very serious questions about Gardasil taken very seriously and answered very seriously, it makes me LIVID. We need more people in the pharmaceutical industry to encourage scientists, physicians and the public to ask intelligent questions and not simply swallow the party line wholesale. So-called reporters like the notorious Express’s Lucy Johnston badly undermine the likelihood of that happening.
If I’ve understood Dr. Harper correctly—forgive me if I haven’t, Dr. Harper, and feel free to correct me—she thinks that HPV vaccines are in general a good thing but that Gardasil should have been introduced more slowly and cautiously; and that perhaps people with family histories of auto-immune disorders should be particularly cautious. She thinks—again, if I understand correctly—that Merck’s unprecedented intensive marketing campaign has oversold Gardasil; that the 3-shot series and its marketing might make women cavalier about still-essential annual exams; that we don’t know how long protection will last.
According to Goldacre, what she doesn’t think is what she was reported as saying in the Express’s article. That the cervical cancer vaccine 'may be riskier and more deadly than the cancer it is designed to prevent.' That the jab 'would do nothing to reduce the rates of cervical cancer in the UK.' Etc., etc., etc.
Goldacre simply contacted Harper directly when he read the article.
“I will explain Harper's position in her own words,” he writes. “They are unambiguous: ‘I did not say that Cervarix was as deadly as cervical cancer. I did not say that Cervarix could be riskier or more deadly than cervical cancer. I did not say that Cervarix was controversial, I stated that Cervarix is not a 'controversial drug'. I did not 'hit out' – I was contacted by the press for facts. And this was not an exclusive interview.”
Harper did not "develop Cervarix" but she did work on some important trials of Gardasil and also Cervarix. "Gardasil is not a 'sister vaccine' as the Express said, it is a different compound. I do not know of the side effects of Cervarix as it is not available in the US.’
“She did not say that Cervarix was being overmarketed. ‘I did say that Merck was egregiously overmarketing Gardasil in the US – but Gardasil and Cervarix are not the same vaccines’…She also suspects from modelling data that for the specific and restricted group of women who are punctilious about attending every single one of their cervical cancer screening appointments, vaccination may have little impact on their risk of death from cancer; but even they will benefit from the reduction in reproductive problems caused by treating pre-cancerous changes in cervical cells.
‘I fully support the HPV vaccines," she says. "I believe that in general they are safe in most women. I told the Express all of this.’”
That was a lot of Goldacre’s column to reproduce. But I think it bears repeating as long as the Sunday Express article inevitably circulates and spawns more mis-information.
But he hit a home run with his latest Bad Science column.
He took apart a front page Sunday Express article that has already been widely disseminated around scare sites on the Internet. Of course, you can’t read it on the Sunday Express site anymore because it's been removed. Probably because Dr Diane Harper, who was quoted as saying that HPV vaccines are more dangerous than cervical cancer, is about to sue the pin-striped pants off the always-lurid Express. Or so I hope.
I’ve often felt sorry for Dr Harper. She seems like a forthright, intelligent scientist who removes herself from Merck’s marketing hysteria to make sensible cautionary comments about the Gardasil vaccine, which she has worked on and in general supports. But her comments are frequently taken out of context and paraded around the web as if she were an anti-vaccine crusader.
As someone who is wary of Gardasil to the point of thus far turning it down for my daughters, who have a family history of autoimmune disease; as someone who would like to see an awful lot of very serious questions about Gardasil taken very seriously and answered very seriously, it makes me LIVID. We need more people in the pharmaceutical industry to encourage scientists, physicians and the public to ask intelligent questions and not simply swallow the party line wholesale. So-called reporters like the notorious Express’s Lucy Johnston badly undermine the likelihood of that happening.
If I’ve understood Dr. Harper correctly—forgive me if I haven’t, Dr. Harper, and feel free to correct me—she thinks that HPV vaccines are in general a good thing but that Gardasil should have been introduced more slowly and cautiously; and that perhaps people with family histories of auto-immune disorders should be particularly cautious. She thinks—again, if I understand correctly—that Merck’s unprecedented intensive marketing campaign has oversold Gardasil; that the 3-shot series and its marketing might make women cavalier about still-essential annual exams; that we don’t know how long protection will last.
According to Goldacre, what she doesn’t think is what she was reported as saying in the Express’s article. That the cervical cancer vaccine 'may be riskier and more deadly than the cancer it is designed to prevent.' That the jab 'would do nothing to reduce the rates of cervical cancer in the UK.' Etc., etc., etc.
Goldacre simply contacted Harper directly when he read the article.
“I will explain Harper's position in her own words,” he writes. “They are unambiguous: ‘I did not say that Cervarix was as deadly as cervical cancer. I did not say that Cervarix could be riskier or more deadly than cervical cancer. I did not say that Cervarix was controversial, I stated that Cervarix is not a 'controversial drug'. I did not 'hit out' – I was contacted by the press for facts. And this was not an exclusive interview.”
Harper did not "develop Cervarix" but she did work on some important trials of Gardasil and also Cervarix. "Gardasil is not a 'sister vaccine' as the Express said, it is a different compound. I do not know of the side effects of Cervarix as it is not available in the US.’
“She did not say that Cervarix was being overmarketed. ‘I did say that Merck was egregiously overmarketing Gardasil in the US – but Gardasil and Cervarix are not the same vaccines’…She also suspects from modelling data that for the specific and restricted group of women who are punctilious about attending every single one of their cervical cancer screening appointments, vaccination may have little impact on their risk of death from cancer; but even they will benefit from the reduction in reproductive problems caused by treating pre-cancerous changes in cervical cells.
‘I fully support the HPV vaccines," she says. "I believe that in general they are safe in most women. I told the Express all of this.’”
That was a lot of Goldacre’s column to reproduce. But I think it bears repeating as long as the Sunday Express article inevitably circulates and spawns more mis-information.
Labels:
bad science,
Cervarix,
Daily Express,
Dr Diane Harper,
Gardasil,
Merck
Thursday, October 1, 2009
Teenager Who Died After Cervarix HPV Shot Had Chest Tumor, Pathologist Says
Natalie Morton, the 14 year old schoolgirl who collapsed right after being given the Cervarix immunization and died just hours later, was suffering from a malignant tumor in her chest.
“The pathologist has confirmed today at the opening of the inquest into the death of Natalie Morton that she died from a large malignant tumor of unknown origin in the heart and lungs,” said Dr Caron Grainger, joint director of public health for NHS Coventry and Coventry city council. “There is no indication that the HPV vaccine, which she had received shortly before her death, was a contributing factor to the death, which could have arisen at any point.”
Cervarix is GlaxoSmithKline’s version of Merck’s Gardasil, a vaccine that protects against two oncogenic strains of HPV (human papillomavirus).
“The pathologist has confirmed today at the opening of the inquest into the death of Natalie Morton that she died from a large malignant tumor of unknown origin in the heart and lungs,” said Dr Caron Grainger, joint director of public health for NHS Coventry and Coventry city council. “There is no indication that the HPV vaccine, which she had received shortly before her death, was a contributing factor to the death, which could have arisen at any point.”
Cervarix is GlaxoSmithKline’s version of Merck’s Gardasil, a vaccine that protects against two oncogenic strains of HPV (human papillomavirus).
Labels:
Cervarix,
chest tumor,
HPV vaccine,
Natalie Morton
Wednesday, September 30, 2009
Schoolgirl’s Death After Cervarix HPV Shot Raises Questions about Screening for Underlying Medical Conditions
Britain’s HPV vaccination program was suspended yesterday and a 200,000-shot batch of Cervarix was recalled after 14-year old Natalie Morton turned pale and collapsed after being vaccinated. She died in hospital just hours later.
Because of the implications of her death, an autopsy was performed very quickly at University Hospital in Coventry, England. Initial results indicate that Ms. Morton’s death was a result of an "underlying medical condition," although no explanation was given as to why the shot apparently—although not definitely—precipitated Ms. Morton’s death.
Questions about rare adverse events associated with both Cervarix and Gardasil frequently center on the difference between causality and the trigger effect. Both Cervarix and Gardasil, for instance, have been associated with autoimmune diseases, which arise in genetically predisposed individuals but require an environmental trigger such as chemical exposure or a vaccination.
Take fifteen year old Jenny Tetlock, who apparently had a predisposition to autoimmune disease as seen in an early childhood skin condition. She died within two years of onset of a very rapidly progressing ALS-like paralysis that began shortly after vaccination with Gardasil; the autopsy showed that she had damage to her spine that was caused by “neurological disease that was mediated by immune responses.”
Although no definitive link with Gardasil has been made, the question still looms large in the minds of concerned scientists, doctors and parents—even if Gardasil didn’t definitively “cause” Ms. Tetlock’s death, did it trigger it? And if so, how do we stop that from happening again? Can we, and should we, insist on a better screening process to find individuals likely to be adversely affected by immunization?
The VAERS passive surveillance system reports eleven cases of cardiac arrest after vaccination with Gardasil. The Advisory Committee on Immunization Practices recommended back in 2003 that military personnel with known underlying heart disease or cardiac risk factors, such as diabetes or a smoking habit, should NOT be given the smallpox vaccine after it was associated with increased cardiac “events.”
And the FDA has found a slightly increased risk of blood clots to be associated with Gardasil, which should raise questions for girls who are on the Pill; and when two girls in Spain suffered repeated convulsions for months after being given the vaccine, an investigation found that the convulsions weren’t caused by Gardasil but could have been triggered by it.
Meanwhile, Dr Caron Grainger, joint director for public health for the National Health Service Coventry and Coventry city council, simply said in a statement: “The preliminary postmortem results have revealed a serious underlying medical condition which was likely to have caused death. We are awaiting further test results which will take some time. However indications are that it was most unlikely that the HPV vaccination was the cause of death.”
NHS officials urged parents not to be alarmed and to allow their children to be vaccinated when the Cervarix program resumes next week. Girls aged 12 and 13 in British schools are given the HPV jab in school unless their parents specifically object. The batch of Cervarix that was used for Natalie Morton’s vaccination has been returned to GlaxoSmithKline for further testing, and schools are awaiting fresh supplies.
Cervarix and Gardasil are both new vaccines against the human papillomavirus, which is usually shrugged off by the immune system but can, in a very tiny percentage of cases, cause cervical cancer and (even more rarely) penile, esophageal, anal or testicular cancer. The vaccines use genetically engineered VLPs (virus-like particles); Cervarix protects against two oncogenic strains of HPV and uses a novel adjuvant, AS04; while Gardasil uses an aluminum adjuvant and protects against two oncogenic strains and two genital wart-causing strains.
Vaccination programs usually work on the “greater good” principle, with the idea that a few patients might experience adverse side effects, even death, but lives will be saved overall. Merck has been widely criticized for its heavy-handed over-selling of Gardasil, notably in last month’s JAMA.
What do you think? Could we do a better job of screening individuals prior to vaccination rather than adopting a “one size fits all” policy?
Because of the implications of her death, an autopsy was performed very quickly at University Hospital in Coventry, England. Initial results indicate that Ms. Morton’s death was a result of an "underlying medical condition," although no explanation was given as to why the shot apparently—although not definitely—precipitated Ms. Morton’s death.
Questions about rare adverse events associated with both Cervarix and Gardasil frequently center on the difference between causality and the trigger effect. Both Cervarix and Gardasil, for instance, have been associated with autoimmune diseases, which arise in genetically predisposed individuals but require an environmental trigger such as chemical exposure or a vaccination.
Take fifteen year old Jenny Tetlock, who apparently had a predisposition to autoimmune disease as seen in an early childhood skin condition. She died within two years of onset of a very rapidly progressing ALS-like paralysis that began shortly after vaccination with Gardasil; the autopsy showed that she had damage to her spine that was caused by “neurological disease that was mediated by immune responses.”
Although no definitive link with Gardasil has been made, the question still looms large in the minds of concerned scientists, doctors and parents—even if Gardasil didn’t definitively “cause” Ms. Tetlock’s death, did it trigger it? And if so, how do we stop that from happening again? Can we, and should we, insist on a better screening process to find individuals likely to be adversely affected by immunization?
The VAERS passive surveillance system reports eleven cases of cardiac arrest after vaccination with Gardasil. The Advisory Committee on Immunization Practices recommended back in 2003 that military personnel with known underlying heart disease or cardiac risk factors, such as diabetes or a smoking habit, should NOT be given the smallpox vaccine after it was associated with increased cardiac “events.”
And the FDA has found a slightly increased risk of blood clots to be associated with Gardasil, which should raise questions for girls who are on the Pill; and when two girls in Spain suffered repeated convulsions for months after being given the vaccine, an investigation found that the convulsions weren’t caused by Gardasil but could have been triggered by it.
Meanwhile, Dr Caron Grainger, joint director for public health for the National Health Service Coventry and Coventry city council, simply said in a statement: “The preliminary postmortem results have revealed a serious underlying medical condition which was likely to have caused death. We are awaiting further test results which will take some time. However indications are that it was most unlikely that the HPV vaccination was the cause of death.”
NHS officials urged parents not to be alarmed and to allow their children to be vaccinated when the Cervarix program resumes next week. Girls aged 12 and 13 in British schools are given the HPV jab in school unless their parents specifically object. The batch of Cervarix that was used for Natalie Morton’s vaccination has been returned to GlaxoSmithKline for further testing, and schools are awaiting fresh supplies.
Cervarix and Gardasil are both new vaccines against the human papillomavirus, which is usually shrugged off by the immune system but can, in a very tiny percentage of cases, cause cervical cancer and (even more rarely) penile, esophageal, anal or testicular cancer. The vaccines use genetically engineered VLPs (virus-like particles); Cervarix protects against two oncogenic strains of HPV and uses a novel adjuvant, AS04; while Gardasil uses an aluminum adjuvant and protects against two oncogenic strains and two genital wart-causing strains.
Vaccination programs usually work on the “greater good” principle, with the idea that a few patients might experience adverse side effects, even death, but lives will be saved overall. Merck has been widely criticized for its heavy-handed over-selling of Gardasil, notably in last month’s JAMA.
What do you think? Could we do a better job of screening individuals prior to vaccination rather than adopting a “one size fits all” policy?
Labels:
adjuvant,
Cervarix,
death,
Gardasil,
HPV vaccine,
Jenny Tetlock,
Natalie Morton,
underlying medical condition
Tuesday, September 29, 2009
Girl, 14, Dies after HPV Vaccine
A post-mortem will be performed today on Natalie Morton, the British schoolgirl who collapsed and died yesterday after receiving her first Cervarix shot. The FDA’s vaccine advisory board recently gave Cervarix the nod for use in the US, but today the FDA again put approval for GlaxoSmithKline’s vaccine against two cancer-causing strains of the human papillomavirus (HPV) on hold because it “needs more time to review the product.”
The National Health Service has taken the suspect batch of Cervarix off its shelves and suspended its HPV vaccination program for a couple of days. Although several other girls complained of feeling faint and ill and asked to go home, it’s not known whether the apparently healthy schoolgirl’s death was caused by a bad batch of the vaccine, or a very rare reaction, or was simply coincidental. Cervarix is given to all Year 8 girls (aged 12-13) in Britain’s schools unless their parents opt out of the vaccination program.
Like Gardasil, Merck’s competing HPV vaccine, Cervarix contains genetically engineered virus-like particles (VLPs) and girls are given three separate shots over several months. However, Gardasil uses a standard aluminum adjuvant to enhance immune response, whereas Cervarix contains AS04, a novel adjuvant that delivers a stronger and more sustained immune response.
Gardasil has been anecdotally associated with multiple deaths and severe adverse events, including rapid onset paralysis, although the FDA insists that the benefits outweigh the risks. A recent report found that there is no conclusive evidence linking Gardasil with any side effects other that syncope and a slightly raised risk of blood clots.
In February 2009 a batch of Gardasil was sequestered in Spain when two young girls started convulsing shortly after the vaccine was administered. The two girls were repeatedly admitted to intensive care in the following months. Spain's vaccination program resumed after an investigation ruled that Gardasil did not cause the convulsions, although it could have “triggered” them. Auto immune diseases arise in genetically predisposed individuals after being triggered by an environmental factor.
The HPV vaccine is typically given to girls as young as 9, but more often around the age of 12, before the start of sexual activity. It isn’t yet known how long the vaccine will protect against the strains of HPV it guards against, whether other strains will fill the biological niche left vacant, or what its effect will be on natural immunity against the virus. Currently, about 80 percent of the population will be infected with one or multiple strains of the virus at some point in their lives but some 95 percent of infections will be shrugged off. Persistent infections can eventually lead to cervical cancer unless caught by a routine annual Pap test. Gardasil has been shown in Merck’s testing to prevent 17-45 percent of cervical abnormalities, not 70-100 percent as is commonly reported.
Gardasil and Cervarix are intended to “kill the invader” (or at least a couple of the invaders—15 strains of HPV out of more than 100 are known to be oncogenic) rather than “strengthen the host” via a strong immune system. Immune systems can be weakened by smoking, insufficient sleep, and poor diet—a 2007 study found that less than 10 percent of American teens get the recommended number of fruits and vegetables in their daily diet. Multiple sexual partners and lack of circumcision also increase the chances of getting a persistent infection.
Although both vaccines are now given only to girls, Gardasil is hoping to widen its market reach soon as FDA approval for its use on boys is anticipated.
The National Health Service has taken the suspect batch of Cervarix off its shelves and suspended its HPV vaccination program for a couple of days. Although several other girls complained of feeling faint and ill and asked to go home, it’s not known whether the apparently healthy schoolgirl’s death was caused by a bad batch of the vaccine, or a very rare reaction, or was simply coincidental. Cervarix is given to all Year 8 girls (aged 12-13) in Britain’s schools unless their parents opt out of the vaccination program.
Like Gardasil, Merck’s competing HPV vaccine, Cervarix contains genetically engineered virus-like particles (VLPs) and girls are given three separate shots over several months. However, Gardasil uses a standard aluminum adjuvant to enhance immune response, whereas Cervarix contains AS04, a novel adjuvant that delivers a stronger and more sustained immune response.
Gardasil has been anecdotally associated with multiple deaths and severe adverse events, including rapid onset paralysis, although the FDA insists that the benefits outweigh the risks. A recent report found that there is no conclusive evidence linking Gardasil with any side effects other that syncope and a slightly raised risk of blood clots.
In February 2009 a batch of Gardasil was sequestered in Spain when two young girls started convulsing shortly after the vaccine was administered. The two girls were repeatedly admitted to intensive care in the following months. Spain's vaccination program resumed after an investigation ruled that Gardasil did not cause the convulsions, although it could have “triggered” them. Auto immune diseases arise in genetically predisposed individuals after being triggered by an environmental factor.
The HPV vaccine is typically given to girls as young as 9, but more often around the age of 12, before the start of sexual activity. It isn’t yet known how long the vaccine will protect against the strains of HPV it guards against, whether other strains will fill the biological niche left vacant, or what its effect will be on natural immunity against the virus. Currently, about 80 percent of the population will be infected with one or multiple strains of the virus at some point in their lives but some 95 percent of infections will be shrugged off. Persistent infections can eventually lead to cervical cancer unless caught by a routine annual Pap test. Gardasil has been shown in Merck’s testing to prevent 17-45 percent of cervical abnormalities, not 70-100 percent as is commonly reported.
Gardasil and Cervarix are intended to “kill the invader” (or at least a couple of the invaders—15 strains of HPV out of more than 100 are known to be oncogenic) rather than “strengthen the host” via a strong immune system. Immune systems can be weakened by smoking, insufficient sleep, and poor diet—a 2007 study found that less than 10 percent of American teens get the recommended number of fruits and vegetables in their daily diet. Multiple sexual partners and lack of circumcision also increase the chances of getting a persistent infection.
Although both vaccines are now given only to girls, Gardasil is hoping to widen its market reach soon as FDA approval for its use on boys is anticipated.
Tuesday, August 18, 2009
Tell the FDA Your Opinion of Gardasil
No doubt the FDA catches some of the rumblings, questions and side-effect horror stories about Merck’s Gardasil that constantly percolate through the internet and media. But now you’ll have a chance to address the agency directly, when the Vaccines and Related Biological Products Advisory Committee meets to discuss the HPV vaccine.
The Committee will meet on September 9, 2009 in Maryland. On the agenda: a discussion about the effectiveness and safety of GlaxoSmithKline’s Cervarix vaccine against the HPV virus for females, and another about the advisability of recommending the Gardasil vaccine for males.
And here’s where you (maybe) come in: the public is invited to make a written or oral presentation of data, information, or a viewpoint about either issue. Background material will hopefully be available online two business days ahead of the meeting; otherwise it will be available after the meeting. Unfortunately only two half-hour public comment sessions are scheduled, so good luck getting in there, but here are the rules anyway.
"Written submissions may be made to the contact person on or before September 4, 2009
Oral presentations from the public will be scheduled between approximately 11:30 a.m. and 12:00 p.m. and 3:40 p.m. and 4:10 p.m.
Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before August 27, 2009. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by September 3, 2009.
Contact Information
Christine Walsh, R.N.1401 Rockville Pike, HFM-71, Rockville, MD 20852301-827-0314FAX: 301-827-0294e-mail: Christine.Walsh@fda.hhs.gov
FDA Advisory Committee Information Line1-800-741-8138 (301-443-0572 in the Washington, DC, area)code 3014512391. Please call the Information Line for up-to-date information on this meeting. "
The Committee will meet on September 9, 2009 in Maryland. On the agenda: a discussion about the effectiveness and safety of GlaxoSmithKline’s Cervarix vaccine against the HPV virus for females, and another about the advisability of recommending the Gardasil vaccine for males.
And here’s where you (maybe) come in: the public is invited to make a written or oral presentation of data, information, or a viewpoint about either issue. Background material will hopefully be available online two business days ahead of the meeting; otherwise it will be available after the meeting. Unfortunately only two half-hour public comment sessions are scheduled, so good luck getting in there, but here are the rules anyway.
"Written submissions may be made to the contact person on or before September 4, 2009
Oral presentations from the public will be scheduled between approximately 11:30 a.m. and 12:00 p.m. and 3:40 p.m. and 4:10 p.m.
Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before August 27, 2009. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by September 3, 2009.
Contact Information
Christine Walsh, R.N.1401 Rockville Pike, HFM-71, Rockville, MD 20852301-827-0314FAX: 301-827-0294e-mail: Christine.Walsh@fda.hhs.gov
FDA Advisory Committee Information Line1-800-741-8138 (301-443-0572 in the Washington, DC, area)code 3014512391. Please call the Information Line for up-to-date information on this meeting. "
Friday, May 8, 2009
Cervarix versus Gardasil
The battle’s on. And let the marketing campaigns and medical sniping begin.
GlaxoSmithKline said today that the results of a comparative HPV vaccine study it had sponsored showed that Cervarix generated between two and six times as many antibodies as Gardasil.
Both vaccines utilize novel “virus-like particles,” VLPs. These are created by inserting DNA into yeast cells to make a genetically-engineered ‘seed stock’. The resulting paste is cultured in a fermenter to increase cell mass and then incubated; eventually the antigen VLPs are filtered from the paste and blended with adjuvants. The paste is then cleaned and reused.
Both vaccines protect against HPV strains 16 and 18, thought to be responsible for 66 to 70 percent of cervical cancers, although one study recently showed 16 to have been losing ground to strains other than 18 (there are believed to be up to 120 strains of HPV) for some years. Gardasil also protects against two wart-causing strains.
But Cervarix also uses a novel adjuvant containing aluminium salt and monophosphoryl lipid A (MPL), and according to GSK that makes a big difference in antibody levels—a claim that made a Merck spokesman sniff disparagingly, “It's disease efficacy that's really the most important, and we certainly have very high efficacy against some very important disease endpoints."
Cervarix has been used in the EU for some time and was chosen over Gardasil by Britain for its country-wide vaccination program. However, the FDA is currently looking it over for approval in the US, where Merck has had the market to itself up until now.
Both vaccines have been associated with side-effects including paralysis, convulsions and immune disorders, although no causal link has been proven and the CDC beleives that HPV vaccines are safe.
Approval for Cervarix in the US could come by the fall—so if you think the Gardasil campaign up to now has been aggressive, honey, you ain’t seen nothin’ yet.
GlaxoSmithKline said today that the results of a comparative HPV vaccine study it had sponsored showed that Cervarix generated between two and six times as many antibodies as Gardasil.
Both vaccines utilize novel “virus-like particles,” VLPs. These are created by inserting DNA into yeast cells to make a genetically-engineered ‘seed stock’. The resulting paste is cultured in a fermenter to increase cell mass and then incubated; eventually the antigen VLPs are filtered from the paste and blended with adjuvants. The paste is then cleaned and reused.
Both vaccines protect against HPV strains 16 and 18, thought to be responsible for 66 to 70 percent of cervical cancers, although one study recently showed 16 to have been losing ground to strains other than 18 (there are believed to be up to 120 strains of HPV) for some years. Gardasil also protects against two wart-causing strains.
But Cervarix also uses a novel adjuvant containing aluminium salt and monophosphoryl lipid A (MPL), and according to GSK that makes a big difference in antibody levels—a claim that made a Merck spokesman sniff disparagingly, “It's disease efficacy that's really the most important, and we certainly have very high efficacy against some very important disease endpoints."
Cervarix has been used in the EU for some time and was chosen over Gardasil by Britain for its country-wide vaccination program. However, the FDA is currently looking it over for approval in the US, where Merck has had the market to itself up until now.
Both vaccines have been associated with side-effects including paralysis, convulsions and immune disorders, although no causal link has been proven and the CDC beleives that HPV vaccines are safe.
Approval for Cervarix in the US could come by the fall—so if you think the Gardasil campaign up to now has been aggressive, honey, you ain’t seen nothin’ yet.
Thursday, March 26, 2009
A New Study on Gardasil / HPV Proves Perplexing
OK, this one has really left me scratching my head, and not a little worried. A new study published in the March 18 Journal of the National Cancer Institute (JNCI) set out to help predict “how HPV vaccination and HPV-based screening will influence cervical cancer prevention.”
Researchers took a look at both early (1213 cases diagnosed from 1985-1999) and invasive (808 cases from 1980-1999) cervical cancers in a New Mexico population.
They found that, yes, the majority—some 66.3 percent—of invasive cancers were indeed caused by the HPV strains 16 and 18 that are targeted by the HPV vaccines Gardasil and its British-born competition, Cervarix.
Type 16 caused 53.2% of invasive cervical cancers, type 18 caused 13.1%, and type 45 was responsible for 6.1%. On the early cancer front, Big Bad 16 lay behind 56.3% of cases, while HPV31 was responsible for 12.6% and HPV33 for 8.0%.
The researchers also found that the women who were diagnosed with invasive cancers caused by HPV16 were diagnosed on average at the age of 48; those with cancers caused by HPV 18 at almost 46; and those with cancers caused by other strains of HPV at the age of 52.3—several years later.
And here’s what’s making me scratch my head. Their discoveries caused the researchers to wonder whether, once sufficient herd immunity to HPVs 16 and 18 had been achieved via Gardasil, women could begin cervical cancer screenings a few years later. After all, if the strains left active generally take longer to cause trouble, wouldn't that make sense?
It’s important to figure this out because the cost-effectiveness of Gardasil is pretty dubious. The three-shot series is expensive, running at $360 plus the cost of administration; health insurance will usually cover a part of the cost. Cash-strapped families aren’t left out—Gardasil is freely available to impecunious girls up to the age of 18 at an estimated cost of $1 billion in taxpayer dollars.
According to the New England Journal of Medicine all those shots for 12-year olds would work out at $43,600 per quality-adjusted life-year (QALY) gained, although a temporary catch-up program for girls up to age 18 would cost $97,300 per QALY, and extending the vaccination program to age 26 would cost $152,700 per QALY
The math just about works for the younger crowd—unless equally expensive booster shots or reformulated shots prove to be necessary, something that Merck flat-out knows nothing about but that many experts consider likely.
So if you could skip a few years of exams, that would make it all sound so much more efficient. (Assuming that you’re happy for your health to be boiled down to a matter of dollars and cents--although, to be fair, early screening is said by some to lead to unnecessary and frightening interventions.)
Just a couple of problems.
When the English branch of Britain’s National Health Service switched the age of young women’s first Pap smear screening from 20 to 25, they found that far fewer women came in for screenings, presumably because they’d never got into the habit. Changing the screening age (currently recommended at age 21 or three years after beginning sexual activity in the US) is a dangerous path to stray down for so many reasons—just for a start, you'd have to assume that patterns of HPV infection wouldn't change. Which leads me to the next issue.
The JNCI study also found that the number of both early and invasive HPV16-caused cancers has been decreasing over the last few years, while the number of cancers caused by HPV strains other than 16 and 18 has been proportionately increasing—an extremely worrisome trend if you are relying on inherently-limited Gardasil, which only targets 16 and 18 for preventing cancer, to take care of you. Even now, this study found that 16 and 18 caused only 66.3% of cervical cancers, while the number had previously been reported at around 70%.
Add to that the threat of replacement disease, whereby other strains happily rush to fill the void left by targeted strains, and our daughters could be left pretty vulnerable.
Probably not the best time to think about delaying screeings.
Researchers took a look at both early (1213 cases diagnosed from 1985-1999) and invasive (808 cases from 1980-1999) cervical cancers in a New Mexico population.
They found that, yes, the majority—some 66.3 percent—of invasive cancers were indeed caused by the HPV strains 16 and 18 that are targeted by the HPV vaccines Gardasil and its British-born competition, Cervarix.
Type 16 caused 53.2% of invasive cervical cancers, type 18 caused 13.1%, and type 45 was responsible for 6.1%. On the early cancer front, Big Bad 16 lay behind 56.3% of cases, while HPV31 was responsible for 12.6% and HPV33 for 8.0%.
The researchers also found that the women who were diagnosed with invasive cancers caused by HPV16 were diagnosed on average at the age of 48; those with cancers caused by HPV 18 at almost 46; and those with cancers caused by other strains of HPV at the age of 52.3—several years later.
And here’s what’s making me scratch my head. Their discoveries caused the researchers to wonder whether, once sufficient herd immunity to HPVs 16 and 18 had been achieved via Gardasil, women could begin cervical cancer screenings a few years later. After all, if the strains left active generally take longer to cause trouble, wouldn't that make sense?
It’s important to figure this out because the cost-effectiveness of Gardasil is pretty dubious. The three-shot series is expensive, running at $360 plus the cost of administration; health insurance will usually cover a part of the cost. Cash-strapped families aren’t left out—Gardasil is freely available to impecunious girls up to the age of 18 at an estimated cost of $1 billion in taxpayer dollars.
According to the New England Journal of Medicine all those shots for 12-year olds would work out at $43,600 per quality-adjusted life-year (QALY) gained, although a temporary catch-up program for girls up to age 18 would cost $97,300 per QALY, and extending the vaccination program to age 26 would cost $152,700 per QALY
The math just about works for the younger crowd—unless equally expensive booster shots or reformulated shots prove to be necessary, something that Merck flat-out knows nothing about but that many experts consider likely.
So if you could skip a few years of exams, that would make it all sound so much more efficient. (Assuming that you’re happy for your health to be boiled down to a matter of dollars and cents--although, to be fair, early screening is said by some to lead to unnecessary and frightening interventions.)
Just a couple of problems.
When the English branch of Britain’s National Health Service switched the age of young women’s first Pap smear screening from 20 to 25, they found that far fewer women came in for screenings, presumably because they’d never got into the habit. Changing the screening age (currently recommended at age 21 or three years after beginning sexual activity in the US) is a dangerous path to stray down for so many reasons—just for a start, you'd have to assume that patterns of HPV infection wouldn't change. Which leads me to the next issue.
The JNCI study also found that the number of both early and invasive HPV16-caused cancers has been decreasing over the last few years, while the number of cancers caused by HPV strains other than 16 and 18 has been proportionately increasing—an extremely worrisome trend if you are relying on inherently-limited Gardasil, which only targets 16 and 18 for preventing cancer, to take care of you. Even now, this study found that 16 and 18 caused only 66.3% of cervical cancers, while the number had previously been reported at around 70%.
Add to that the threat of replacement disease, whereby other strains happily rush to fill the void left by targeted strains, and our daughters could be left pretty vulnerable.
Probably not the best time to think about delaying screeings.
Labels:
Cervarix,
Gardasil,
Gardasil vaccine,
HPV vaccine,
Journal of the National Cancer Institute,
Pap smear
Subscribe to:
Posts (Atom)
